Berlin Cures Holding AG | Finanzwire

Basculer en Français

8295	Companies
114831	Keywords
55272	Articles
62429	Press releases

Headlines Articles Press releases Berlin Cures Holding AG

Home
Companies
Berlin Cures Holding AG

BRIEF

published on 08/29/2024 at 08:05, 2 months 23 days ago

Berlin Cures Welcomes Renowned Immunologist Professor Danny Altmann to its Advisory Board

Advisory Board Long Covid Clinical Trials Immunology Biomedical Research
PRESS RELEASE

published on 08/29/2024 at 08:00, 2 months 23 days ago

Berlin Cures Welcomes Renowned Immunologist Professor Danny Altmann to its Advisory Board
Berlin Cures appoints immunologist Professor Danny Altmann to Advisory Board for drug research and development in autoimmune diseases, including Long COVID

Advisory Board Long Covid Berlin Cures Autoimmune Diseases Danny Altmann
BRIEF

published on 06/26/2024 at 08:05, 4 months 25 days ago

Berlin Cures Announces Changes to Board of Directors to Propel Development of BC 007

Board Of Directors Long Covid Drug Development Berlin Cures BC 007
PRESS RELEASE

published on 06/26/2024 at 08:00, 4 months 25 days ago

Berlin Cures announces changes to Board of Directors to further propel the development of BC 007
Berlin Cures appoints Craig T. Basson, Gerrard Terlouw, and Oliver von Stein to its Board of Directors to drive development of BC 007 for Long COVID and cardiovascular disease

Board Of Directors Long Covid Berlin Cures BC 007 Cardiovascular Disease
BRIEF

published on 04/23/2024 at 08:05, 6 months 28 days ago

Berlin Cures Completes Screening Phase of BC 007 Trial in Fight Against Long COVID

Clinical Research Berlin Cures Phase II Trial BC 007 Long COVID Treatment
PRESS RELEASE

published on 04/23/2024 at 08:00, 6 months 28 days ago

Screening completed: Berlin Cures achieves key milestone in BC 007 Phase II Trial for treatment of Long COVID
Berlin Cures achieves key milestone in BC 007 Phase II trial for Long COVID treatment by successfully completing patient screening, marking a significant step in developing an effective therapy

Berlin Cures Phase II Trial BC 007 Long COVID Treatment Patient Screening
BRIEF

published on 04/03/2024 at 08:05, 7 months 18 days ago

Berlin Cures Boosts Research and Development with New Advisory Board

Biotechnology Advisory Board Long Covid Clinical Trial Berlin Cures
PRESS RELEASE

published on 04/03/2024 at 08:00, 7 months 18 days ago

Berlin Cures Expands Research Capabilities and Scientific Expertise with New Advisory Board
Berlin Cures appoints six renowned scientists to new advisory board to enhance research capabilities and support market launch of therapies, including for Long COVID

Advisory Board Long Covid Berlin Cures Scientists Research Capabilities
BRIEF

published on 03/04/2024 at 12:05, 8 months 16 days ago

Berlin Cures Reaches Key Milestone in Phase II Trial for Long COVID Treatment

Long Covid Berlin Cures Phase II Trial BC 007 Autoimmune Diseases
PRESS RELEASE

published on 03/04/2024 at 12:00, 8 months 16 days ago

Berlin Cures' BC 007 Targets Long COVID: Solid Phase II Trial Progress with Over 50% Patient Recruitment
Berlin Cures reaches over 50% patient recruitment in Phase II trial for Long COVID treatment with BC 007, aiming to neutralize harmful autoantibodies. CEO emphasizes global impact and urgent need for innovative solutions

Long Covid Berlin Cures Phase II Trial Autoantibodies Innovative Treatment

Accesswire

Published on 11/21/2024 at 10:03, 36 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 39 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 39 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 10 hours 4 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 14 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 10:04, 34 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 37 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 39 minutes ago

Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 39 minutes ago

Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV
Published on 11/21/2024 at 09:01, 1 hour 38 minutes ago

Original-Research: Netfonds AG (von NuWays AG): Buy

Les Echos

Published on 11/21/2024 at 06:58, 3 hours 41 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 19 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 16 hours 54 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 16 hours 54 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 2 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE